Rina
Hui
Rina Hui is a Clinical Professor and the Director of the Centre of Cancer Medicine at the University of Hong Kong. She has a clinical and research focus on breast and lung cancers. Rina also serves as a member of the Senate, a member of the Honorary Fellowships Committee and chairs the Committee of Discontinuation at the University of Hong Kong. Rina is a steering committee member of the Hong Kong Breast Cancer Registry and a council member of the Hong Kong Cancer Therapy Society. After completing her medical degree at The University of Sydney and specialist training at the Royal North Shore Hospital, Rina undertook translational research in cyclin D1-CDK4/6-p16INK4a-pRb pathway in breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree. Before joining HKU in January 2023, Rina was a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at Westmead Hospital, Australia. She previously served as Co-chair of Oncology Block at the Sydney Medical School, the University of Sydney and served in the written examination committee for the Royal Australasian College of Physician. She was the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Basic Sciences of Oncology Course Subject Matter Expert Group. Rina serves on the Education Committee for International Association for the Study of Lung Cancer (IASLC) and was a member of the scientific program committee for European Society of Medical Oncology Congress in 2021 and 2022. Rina has been principal investigator on many clinical trials, including phase I as well as many landmark practice-changing phase III clinical studies of immunotherapy and targeted therapies in breast and lung cancers, resulting in publications in highly ranked journals.